Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  clofarabine
Find trials that include:  Any drugs shown
Trial Status:  Active
Results 1-25 of 37 for your search:
Start Over
Clofarabine or High-Dose Cytarabine and Pegaspargase in Children With ALL
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 1 to 17
Sponsor: Other
Protocol IDs: CDR0000686545, 2009-012758-18, GPOH-COALL-08-09, EUDRACT-2009-012758-18, EU-21076, NCT01228331
Total Therapy Study XVI for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and under
Sponsor: NCI, Other
Protocol IDs: TOTXVI, 5R01CA140729, 5F32CA141762, R37CA036401, 5R01CA090246, Aspar PK-PD-T16, NCI-2011-01254, NCT00549848
Clofarabine Plus Cytarabine Versus Conventional Induction Therapy And A Study Of NK Cell Transplantation In Newly Diagnosed Acute Myeloid Leukemia
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 21 and under
Sponsor: NCI, Other
Protocol IDs: AML08, 5R01CA138744, 1R01CA115422, NCT00703820
Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 60 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000659585, ECOG-E2906, E2906, NCT01041703
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 1 to 30
Sponsor: NCI, Other
Protocol IDs: AALL1131, NCI-2011-03797, CDR0000706370, U10CA098543, COG-AALL1131, NCT01406756
Fludarabine-IV Busulfan ± Clofarabine and Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
Phase: Phase III
Type: Treatment
Status: Active
Age: 3 to 70
Sponsor: Other
Protocol IDs: 2011-0628, NCI-2012-00038, NCT01471444
Clofarabine for Relapsed or Refractory T-Cell or B-Cell Non-Hodgkin Lymphoma (NHL)
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 1066306 (0408), NCT00156013
Clofarabine, Cytarabine, and Idarubicin in Treating Patients With Intermediate-Risk or High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplasia
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 60
Sponsor: Other
Protocol IDs: EORTC-06061, EU-20905, 2006-004912-28, GIMEMA-AML-14A, EudraCT-2006-004912-28, NCT00838240
Clofarabine, Idarubicin, and Cytarabine (CIA) Versus Fludarabine, Idarubicin, and Cytarabine (FLAI) in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2010-0788, NCI-2011-00251, NCT01289457
Clofarabine Pre-conditioning With Allogeneic Transplant for Acute Myeloid Leukaemia (AML)
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: RHM CAN0638, 2008-007043-14, NCT01422603
Dose Escalation of Clofarabine in Combination With Cytarabine and Idarubicin as Induction Therapy in High Risk AML
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: KS-2009-003, 2010-021719-18, NCT01534702
Allogeneic Stem Cell Transplant for Chronic Lymphocytic Leukemia (CLL)
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 to 70
Sponsor: Other
Protocol IDs: 2012-0249, NCI-2012-01248, NCT01629511
Gemcitabine/Clofarabine/Busulfan and Allogeneic Transplantation for Aggressive Lymphomas
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 12 to 65
Sponsor: Other
Protocol IDs: 2012-0506, NCI-2012-02055, NCT01701986
Decitabine Followed by Clofarabine, Idarubicin, and Cytarabine in Acute Leukemia
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 64
Sponsor: Other
Protocol IDs: 2012-1064, NCI-2013-00548, NCT01794702
Mitoxantrone and Clofarabine for Treatment of Recurrent NHL or Acute Leukemia
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 30 and under
Sponsor: Other
Protocol IDs: NYMC 542, L 10, 819, NCT01842672
Haplo-identical SCT for HR Hematologic Malignancies w/Post-Transplant In-Vivo T-cell Depletion
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: SCT 0813 Haplo, NCT02053545
Thiotepa-Clofarabine-Busulfan With Allogeneic Stem Cell Transplant for High Risk Malignancies
Phase: Phase II
Type: Treatment
Status: Active
Age: Under 60
Sponsor: Other
Protocol IDs: 2008-0363, NCI-2012-01630, NCT00857389
The CLARA Study From the Acute Leukemia French Association (ALFA 0702 Trial)
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 60
Sponsor: Other
Protocol IDs: 2006.456/50, NCT00932412
Busulfan Plus Clofarabine Followed by Allogeneic Hematopoietic Stem Cell Transplantation
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 0 to 65
Sponsor: Other
Protocol IDs: 2009-0209, NCI-2012-01270, NCT00990249
Clofarabine and Low-Dose Total-Body Irradiation in Treating Patients With Acute Myeloid Leukemia Undergoing Donor Peripheral Blood Stem Cell Transplant
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: not specified
Sponsor: NCI, Other
Protocol IDs: 2430.00, NCI-2010-02247, 2430.00A, P30CA015704, P01CA018029, NCT01252667
ClAraC or FLAMSA Followed by Stem Cell Transplantation to Treat High Risk AML or Advanced MDS
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: ClAraC-SCT-01, NCT01423175
Clofarabine Plus Low-Dose Cytarabine for Patients With Higher-Risk Myelodysplastic Syndrome (MDS)
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2011-0660, NCI-2011-03436, NCT01444742
Start Over